Blair William & CO Arbutus Biopharma Corp Transaction History

Blair William & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$1.46 - $4.44 $18,542 - $56,388	-12,700 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$3.41 - $4.57 $1,705 - $2,285	500 Added 4.1%	12,700 $45,000
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $7,350 - $20,286	2,100 Added 20.79%	12,200 $47,000
Q3 2018 Nov 13, 2018	BUY	$7.85 - $12.35 $785 - $1,235	100 Added 1.0%	10,100 $95,000
Q2 2018 Aug 13, 2018	BUY	$5.0 - $7.35 $50,000 - $73,500	10,000 New	10,000 $73,000

156

99.6M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $511M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.